Targets › PAH
12 programs from 10 companies in 14 trials: 9 Phase 1, 2 Phase 3, 2 Phase 4, 1 Phase 2; Metabolic and endocrine, Cardiovascular, Genitourinary; next expected readout Apr 2027.
Catalyzes the hydroxylation of L-phenylalanine to L-tyrosine. (UniProt, P00439)
Open in Phaseline: the race on PAH, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| BioMarin Pharmaceutical | Pegvaliase Phenylalanine ammonia-lyase (PAL) enzyme - degrades phenylalanine to ammonia and trans-cin | PAH | Phase 4 | Phenylketonuria; Phenylketonuria (PKU) | Sep 2027 |
| BioMarin Pharmaceutical | Palynziq Pegvaliase (PEGylated recombinant phenylalanine ammonia-lyase) | PAH | Phase 4 | Phenylketonuria | – |
| PTC Therapeutics | Sepiapterin tetrahydrofolate (BH4) cofactor precursor; increases production of tetrahydropterin (BH4) | PAH | Phase 3 | Phenylketonuria | Feb 2031 |
| Emory University | Sapropterin Phenylalanine-4-hydroxylase activator | PAH | Phase 2 | Renal Insufficiency, Chronic | Apr 2027 |
| Chongqing Peg-Bio Biopharm | PL54 PEGylated recombinant phenylalanine ammonia-lyase | PAH | Phase 1 | Phenylketonuria (PKU) | Jun 2027 |
| Louis Messina | Sapropterin Phenylalanine-4-hydroxylase activator | PAH | Phase 1 | Claudication, Intermittent | Jul 2027 |
| NGGT (Suzhou) Biotechnology | NGGT002 adeno-associated viral vector with human phenylalanine hydroxylase gene | PAH | Phase 1 | Phenylketonurias | Aug 2027 |
| BioMarin Pharmaceutical | BMN 307 AAV gene therapy delivering phenylalanine hydroxylase (PAH) gene | PAH | Phase 1 | Phenylketonuria (PKU) | Dec 2027 |
| Agios Pharmaceuticals | AG-181 Phenylalanine hydroxylase (PAH) activator | PAH | Phase 1 | Phenylketonuria | Jan 2028 |
| VA Office of Research and Development | Sapropterin Phenylalanine-4-hydroxylase activator | PAH | Phase 1 | Heart Failure With Preserved Ejection Fraction | Sep 2028 |
| NGGT | NGGT002 Adeno-associated viral vector with human phenylalanine hydroxylase gene | PAH | Phase 1 | Phenylketonurias | Dec 2030 |
| Sohag University | Sapropterin Dihydrochloride Phenylalanine-4-hydroxylase activator | PAH | Phase 1 | Phenylketonuria (PKU) | – |
Phenylketonuria (4) Phenylketonuria (PKU) (4) Phenylketonurias (2) Claudication, Intermittent (2) Heart Failure With Preserved Ejection Fraction (1) Renal Insufficiency, Chronic (1)
small molecule (8), protein or peptide (2), other (2)
BioMarin Pharmaceutical (3) PTC Therapeutics (1) Chongqing Peg-Bio Biopharm (1) Sohag University (1) NGGT (1) Agios Pharmaceuticals (1) VA Office of Research and Development (1) Emory University (1) NGGT (Suzhou) Biotechnology (1) Louis Messina (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.